Ascendis Pharma A/S (NASDAQ:ASND – Free Report) – Equities research analysts at HC Wainwright cut their Q3 2026 earnings per share (EPS) estimates for Ascendis Pharma A/S in a research note issued on Monday, August 31st. HC Wainwright analyst M. Kapoor now expects that the biotechnology company will earn $1.09 per share for the quarter, down from their previous estimate of $1.16. HC Wainwright has a “Buy” rating and a $345.00 price target on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is $3.90 per share. HC Wainwright also issued estimates for Ascendis Pharma A/S’s Q4 2026 earnings at $1.58 EPS, Q1 2027 earnings at $1.65 EPS, Q2 2027 earnings at $2.34 EPS, Q3 2027 earnings at $3.04 EPS, Q4 2027 earnings at $4.23 EPS and FY2027 earnings at $11.25 EPS.
A number of other equities research analysts have also recently issued reports on ASND. TD Cowen boosted their price objective on Ascendis Pharma A/S from $325.00 to $341.00 and gave the company a “buy” rating in a research note on Friday, August 14th. Jefferies Financial Group reduced their target price on shares of Ascendis Pharma A/S from $333.00 to $330.00 and set a “buy” rating for the company in a research note on Monday. Oppenheimer reissued an “outperform” rating on shares of Ascendis Pharma A/S in a research report on Tuesday, June 9th. Citigroup assumed coverage on shares of Ascendis Pharma A/S in a report on Monday, May 18th. They issued a “buy” rating and a $355.00 price objective for the company. Finally, UBS Group set a $345.00 price target on Ascendis Pharma A/S in a research report on Monday. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $304.95.
Ascendis Pharma A/S Stock Up 6.1%
ASND stock opened at $263.04 on Tuesday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.32 and a current ratio of 2.99. The company has a market capitalization of $16.41 billion, a price-to-earnings ratio of 20.41 and a beta of 0.39. Ascendis Pharma A/S has a fifty-two week low of $186.05 and a fifty-two week high of $282.15. The stock has a fifty day moving average of $256.44 and a 200-day moving average of $239.47.
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last released its earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). The firm had revenue of $387.22 million during the quarter, compared to analysts’ expectations of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the company. Advisory Services Network LLC purchased a new stake in shares of Ascendis Pharma A/S in the third quarter worth $26,000. Arax Advisory Partners grew its position in Ascendis Pharma A/S by 212.2% during the fourth quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock worth $33,000 after buying an additional 104 shares in the last quarter. Leonteq Securities AG bought a new position in Ascendis Pharma A/S in the 4th quarter worth about $36,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Ascendis Pharma A/S during the 4th quarter valued at about $42,000. Finally, Global Retirement Partners LLC boosted its position in shares of Ascendis Pharma A/S by 111.9% during the 4th quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 113 shares during the last quarter.
Insider Transactions at Ascendis Pharma A/S
In other news, Director Jean Jacques Bienaime bought 2,000 shares of the stock in a transaction on Friday, August 14th. The shares were acquired at an average cost of $246.33 per share, for a total transaction of $492,660.00. Following the purchase, the director directly owned 2,900 shares of the company’s stock, valued at $714,357. This trade represents a 222.22% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 40.00% of the stock is owned by corporate insiders.
Ascendis Pharma A/S News Summary
Here are the key news stories impacting Ascendis Pharma A/S this week:
- Positive Sentiment: Ascendis Pharma entered a binding term sheet with BioMarin Pharmaceutical for a global settlement and license agreement related to YUVIWEL (navepegritide). The agreement is intended to resolve all litigation and disputes between the companies, reducing legal uncertainty and potentially improving the commercial outlook for the product. The market reacted favorably, with shares rising after the announcement. Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL
- Positive Sentiment: Analysts continue to rate ASND positively. HC Wainwright maintained a Buy rating and a $345 price target, while Bank of America retained its Buy rating with a $304 target, both implying upside from the stock’s referenced $263.04 level. The stock also received an average Buy rating from covering analysts. Ascendis Pharma Receives Average Rating of Buy from Analysts
- Neutral Sentiment: Bank of America trimmed its price target modestly from $306 to $304 while keeping a Buy rating, signaling slightly reduced valuation expectations but continued confidence in Ascendis Pharma’s prospects.
- Negative Sentiment: HC Wainwright lowered its EPS forecasts for every reported period from the third quarter of 2026 through the fourth quarter of 2027. Its FY2027 estimate fell to $11.25 from $11.88, while quarterly estimates were reduced by $0.07 to $0.19. These revisions indicate that the analyst expects somewhat slower near-term earnings growth, despite maintaining the Buy rating and $345 target.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.
The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.
Read More
- Five stocks we like better than Ascendis Pharma A/S
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
